Publications by authors named "Marie-Michele Trancart"

1. We have applied the concept of using MBIs to produce CYP-Silensomes to quantify the contribution of the major CYPs to drug metabolism (fmCYP). 2.

View Article and Find Full Text PDF

1. Among the different in vitro studies recommended by the regulatory agencies, no gold-standard model can easily and directly measure the quantitative CYP450 contributions to drug biotransformation. In this article, we propose an original strategy, called Silensomes, to produce human liver microsomes silenced for one specific CYP450, thanks to specific mechanism-based inhibitors (MBI).

View Article and Find Full Text PDF

Drug metabolism in liver is the major pathway for xenobiotic elimination from the body. Access to intracellular metabolising enzymes is possible through passive diffusion of lipophilic drugs through cell membrane or active uptake of more polar drugs by specific uptake transporters. Organic Anion Transporting Polypeptides (OATP/SLCO) and Organic Cation Transporters (OCT/SLC22A) are among the most important transporters involved in xenobiotic transport into hepatocytes.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Marie-Michele Trancart"

  • - Marie-Michele Trancart's research primarily focuses on the quantification of cytochrome P450 (CYP) contributions to drug metabolism, employing innovative in vitro models such as Silensomes to enhance the understanding of drug clearance mechanisms.
  • - Her studies have introduced a novel strategy for creating human liver microsomes that are selectively silenced for specific CYP450 enzymes, thereby providing a more direct method for evaluating their roles in drug biotransformation compared to existing models.
  • - Trancart also investigates the effects of cryopreservation on the activity of important hepatic transporters, such as OATP1B1/3 and OCT1, highlighting the complexities of drug metabolism and transport in isolated human hepatocytes.